Agents worth testing in combination studies include FLT3 inhibitors in AML, BCR signaling inhibitors in certain NHL subtypes, and BH3 mimetic drugs (BCL2 inhibitor venetoclax and MCL-1 inhibitors) in a variety of blood cancers. Here, BCR is linked to non-Hodgkin lymphoma.